Elsevier

Clinical Therapeutics

Volume 29, Issue 4, April 2007, Pages 602-610
Clinical Therapeutics

Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial

https://doi.org/10.1016/j.clinthera.2007.03.015Get rights and content

Abstract

Background:

The autonomic nervous system plays an important part in the homeostasis of blood pressure (BP), and sympathetic overactivity may contribute to metabolic conditions such as glycemic intolerance or insulin resistance.

Objective:

This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension.

Methods:

This was a study in patients with type 2 diabetes previously untreated with medication and untreated mild hypertension (diastolic blood pressure [DBP] >90 and <105 mm Hg). For the first 3 months of the study, all patients were treated for hypertension with moxonidine 0.2 mg once daily (M0.2) to establish a moxonidine baseline. After this single-arm period, patients were randomized to receive double-blind treatment with moxonidine 0.2 mg BID (M0.4) or moxonidine 0.2 mg plus irbesartan 150 mg (M0.2+1) once daily for 3 months. Changes in DBP, systolic blood pressure (SBP), body mass index (BMI), fasting and postprandial plasma glucose (FPG and PPG), fasting and postprandial plasma insulin (FPI and PPI), glycosylated hemoglobin (HbA1c), Homeostasis Model Assessment of insulin sensitivity (HOMA-S), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were evaluated at baseline, 3 months (end of single arm period), and 6 months (end of randomized treatment period).

Results:

The study enrolled 99 patients (50 men, 49 women; mean [SD] age, 55 [7] years; mean BMI, 26.8 [0.9]). No significant changes in BMI, PPG, PPI, TC, or LDL-C were observed over the entire study period. At 3 months, treatment with M0.2 was associated with significant improvements from baseline in SBP and DBP (P < 0.05), whereas there were no significant changes in HbA1c, FPG, FPI, HOMA-S, HDL-C, or TG. At 6 months, significant decreases from baseline in HbA1c, FPG, FPI, HOMA-S, and TG were observed in the M0.4 group (all, P < 0.05), but not in the M0.2+1 group. The M0.4 group also had a significant increase from baseline in HDL-C (P < 0.05) that was not seen in the M0.2+1 group. The changes in FPI and HOMA-S were significantly greater in the M0.4 group compared with the M0.2+1 group (P < 0.05). Significant decreases from baseline in SBP and DBP were observed in both the M0.4 and M0.2+1 groups (P < 0.02 and P < 0.01, respectively). No patient withdrew from the study because of a drug-related adverse event, and there were no clinically significant drug-related changes in laboratory values during the study.

Conclusion:

In these patients with type 2 diabetes and mild hypertension, the M0.4 group had greater improvements in measures of glucose metabolism and the plasma lipid profile compared with those treated with M0.2+1.

References (38)

  • MogensenC.E. et al.

    Prevention of diabetic renal disease with special reference to microalbuminuria

    Lancet

    (1995)
  • McInnesG.T.

    Lowering blood pressure for cardiovascular risk reduction

    J Hypertens Suppl

    (2005)
  • ManriqueC.M. et al.

    Hypertensiona treatable component of the cardiometabolic syndrome: Challenges for the primary care physician

    J Clin Hypertens (Greenwich)

    (2006)
  • O'ShaughnessyI.M. et al.

    Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance

    Curr Opin Cardiol

    (1993)
  • KraussR.M.

    Lipids and lipoproteins in patients with type 2 diabetes

    Diabetes Care

    (2004)
  • BonoraE. et al.

    Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: Prospective data from the Bruneck study

    Diabetes Care

    (2003)
  • KnowlerW.C. et al.

    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

    N Eng J Med

    (2002)
  • MontaniJ.P. et al.

    Pathways from obesity to hypertension: From the perspective of a vicious triangle

    Int J Obes Relat Metab Disord

    (2002)
  • ErnsbergerP. et al.

    Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease

    Rev Contemp Pharmacother

    (1998)
  • American Diabetes Association

    Screening for diabetes (Position Statement)

    Diabetes Care

    (2001)
  • Guidelines Subcommittee

    1999 World Health OrganizationInternational Society of Hypertension Guidelines for the Management of Hypertension

    J Hypertens

    (1999)
  • SteinessI.

    Vibratory perception in diabetics during arrested blood flow to the limb

    Acta Med Scand

    (1959)
  • American Diabetes Association

    Nutrition recommendations and principles for people with diabetes mellitus (Position Statement)

    Diabetes Care

    (2001)
  • European Diabetes Policy Group 1999

    A desktop guide to Type 2 diabetes mellitus

    Diabet Med

    (1999)
  • HedingL.G.

    Determination of total serum insulin (IRI) in insulin-treated diabetic patients

    Diabetologia

    (1972)
  • BunnH.F. et al.

    The glycosylation of hemoglobin: Relevance to diabetes mellitus

    Science

    (1978)
  • BornerK. et al.

    Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II)

    J Clin Chem Clin Biochem

    (1978)
  • WahlefeldA.W.

    Triglycerides: Determination after enzymatic hydrolysis

  • Cited by (18)

    • Innervation of the arterial wall and its modification in atherosclerosis

      2015, Autonomic Neuroscience: Basic and Clinical
      Citation Excerpt :

      In animal models, blockage of perivascular vasomotor nerves results in seriously impaired endothelial function (Burnstock, 1990). In hypertensive patients, treatment with monoxidine, an α2-adrenoreceptor agonist, has been shown to have beneficial effects on endothelial function (Topal et al., 2006; Derosa et al., 2007). Therefore, sympathetic nerves could influence endothelial function involved in the regulation of vascular tone.

    • An "I" on Cardiac Hypertrophic Remodelling: Imidazoline Receptors and Heart Disease

      2012, Canadian Journal of Cardiology
      Citation Excerpt :

      In addition, moxonidine results in a clinically relevant reduction in blood pressure and muscle sympathetic nerve activity in patients with renal disease, in end-stage renal disease patients, and patients with resistant hypertension;34-36 and may be an “add-on” treatment in elderly patients whose hypertension is poorly controlled despite treatment with 2 or more antihypertensive agents.35 Moxonidine can be combined with peripheral vasodilators and thiazide diuretics,37 which otherwise may further stimulate SNS activity,38 as well as with angiotensin blockers.28,34 Furthermore, moxonidine potentiates the antidepressant effects of fluoxetine and paroxetine, at doses inefficient by themselves.39

    • Cardiovascular Therapies and Associated Glucose Homeostasis. Implications Across the Dysglycemia Continuum

      2009, Journal of the American College of Cardiology
      Citation Excerpt :

      The mechanism of this benefit is also unclear, but in vitro and animal studies suggest ranolazine may increase glucose-stimulated insulin secretion and this may be responsible for the improved glucose homeostasis observed (68). Moxonidine is a selective imidazole II-receptor agonist that lowers BP by a central mechanism but also has been shown to have dose-dependent metabolic effects including reduction in glucose, insulin, and glycated hemoglobin in those with diabetes and MetSyn (69,70). The prevalence of pre-diabetes and diabetes continues to increase, driven largely by obesity and physical inactivity.

    View all citing articles on Scopus
    View full text